Acquisition of carbapenem-resistant Gram-negative bacilli in intensive care unit: Predictors and molecular epidemiology

Medecine et Maladies Infectieuses

Volumn 45, Issue 1-2, 2015, Pages 34-40

  Marchenay, P ^a   Blasco, G ^b   Navellou, J C ^b   Leroy, J ^a,b   Cholley, P ^a,c   Talon, D ^a,c   Bertrand, X ^a,c   Gbaguidi Haore, H ^a,c  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b UNIVERSITY HOSPITAL OF BESANÇON   (France)

^c UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

Antibiotic resistance; Carbapenem use; Cross transmission; Gram negative bacilli; ICU

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; CARBAPENEM; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; FOSFOMYCIN; OFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; SULFAMETHOXAZOLE; TIGECYCLINE; CARBAPENEM DERIVATIVE;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM DETECTION; BACTERIUM ISOLATE; COHORT ANALYSIS; DISK DIFFUSION; DNA MICROARRAY; ENTEROBACTER CLOACAE; FEMALE; GENOTYPE; GRAM NEGATIVE BACTERIUM; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EPIDEMIOLOGY; NONHUMAN; OBSERVATIONAL STUDY; PREVALENCE; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; PULSED FIELD GEL ELECTROPHORESIS; RISK ASSESSMENT; RISK FACTOR; STENOTROPHOMONAS MALTOPHILIA; TREATMENT DURATION; AGED; DRUG EFFECTS; MIDDLE AGED;

AGED; BETA-LACTAM RESISTANCE; CARBAPENEMS; FEMALE; GRAM-NEGATIVE BACTERIA; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84926178208     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2014.12.003     Document Type: Article

References (26)

1. Canton R., Novais A., Valverde A., Machado E., Peixe L., Baquero F., et al. Prevalence and spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Europe. Clin Microbiol Infect 2008, 14(Suppl. 1):144-153.
2. Pitout J.D., Laupland K.B. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008, 8:159-166.
3. Rogers B.A., Sidjabat H.E., Paterson D.L. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother 2011, 66:1-14.
4. Leverstein-van Hall M.A., Dierikx C.M., Cohen Stuart J., Voets G.M., van den Munckhof M.P., van Essen-Zandbergen A., et al. Dutch patients, retail chicken meat and poultry share the same ESBL genes, plasmids and strains. Clin Microbiol Infect 2011, 17:873-880.
5. Valverde A., Grill F., Coque T.M., Pintado V., Baquero F., Canton R., et al. High rate of intestinal colonization with extended-spectrum-beta-lactamase-producing organisms in household contacts of infected community patients. J Clin Microbiol 2008, 46:2796-2799.
6. Nicolas-Chanoine M.H., Gruson C., Bialek-Davenet S., Bertrand X., Thomas-Jean F., Bert F., et al. 10-Fold increase (2006-11) in the rate of healthy subjects with extended-spectrum beta-lactamase-producing Escherichia coli faecal carriage in a Parisian check-up centre. J Antimicrob Chemother 2013, 68:562-568.
7. Miriagou V., Cornaglia G., Edelstein M., Galani I., Giske C.G., Gniadkowski M., et al. Acquired carbapenemases in Gram-negative bacterial pathogens: detection and surveillance issues. Clin Microbiol Infect 2010, 16:112-122.
8. Nordmann P., Cuzon G., Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009, 9:228-236.
9. Pitout J.D. Multiresistant Enterobacteriaceae: new threat of an old problem. Expert Rev Anti Infect Ther 2008, 6:657-669.
10. Cholley P., Thouverez M., Hocquet D., van der Mee-Marquet N., Talon D., Bertrand X. Most multidrug-resistant Pseudomonas aeruginosa isolates from hospitals in eastern France belong to a few clonal types. J Clin Microbiol 2011, 49:2578-2583.
11. Vettoretti L., Floret N., Hocquet D., Dehecq B., Plesiat P., Talon D., et al. Emergence of extensive-drug-resistant Pseudomonas aeruginosa in a French university hospital. Eur J Clin Microbiol Infect Dis 2009, 28:1217-1222.
12. Carmeli Y., Lidji S.K., Shabtai E., Navon-Venezia S., Schwaber M.J. The effects of group 1 versus group 2 carbapenems on imipenem-resistant Pseudomonas aeruginosa: an ecological study. Diagn Microbiol Infect Dis 2011, 70:367-372.
13. Boucher H.W., Talbot G.H., Bradley J.S., Edwards J.E., Gilbert D., Rice L.B., et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:1-12.
14. van Belkum A., Tassios P.T., Dijkshoorn L., Haeggman S., Cookson B., Fry N.K., et al. Guidelines for the validation and application of typing methods for use in bacterial epidemiology. Clin Microbiol Infect 2007, 13(Suppl. 3):1-46.
15. Armand-Lefevre L., Angebault C., Barbier F., Hamelet E., Defrance G., Ruppe E., et al. Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother 2013, 57:1488-1495.
16. Harris A.D., Johnson J.K., Thom K.A., Morgan D.J., McGregor J.C., Ajao A.O., et al. Risk factors for development of intestinal colonization with imipenem-resistant Pseudomonas aeruginosa in the intensive care unit setting. Infect Control Hosp Epidemiol 2011, 32:719-722.
17. Hyle E.P., Ferraro M.J., Silver M., Lee H., Hooper D.C. Ertapenem-resistant Enterobacteriaceae: risk factors for acquisition and outcomes. Infect Control Hosp Epidemiol 2010, 31:1242-1249.
18. Fortaleza C.M., Freire M.P., Filho Dde C., de Carvalho Ramos M. Risk factors for recovery of imipenem- or ceftazidime-resistant Pseudomonas aeruginosa among patients admitted to a teaching hospital in Brazil. Infect Control Hosp Epidemiol 2006, 27:901-906.
19. Harris A.D., Smith D., Johnson J.A., Bradham D.D., Roghmann M.C. Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin Infect Dis 2002, 34:340-345.
20. Gbaguidi-Haore H., Dumartin C., L'Heriteau F., Pefau M., Hocquet D., Rogues A.M., et al. Antibiotics involved in the occurrence of antibiotic-resistant bacteria: a nationwide multilevel study suggests differences within antibiotic classes. J Antimicrob Chemother 2013, 68:461-470.
21. Onguru P., Erbay A., Bodur H., Baran G., Akinci E., Balaban N., et al. Imipenem-resistant Pseudomonas aeruginosa: risk factors for nosocomial infections. J Korean Med Sci 2008, 23:982-987.
22. Lautenbach E., Weiner M.G., Nachamkin I., Bilker W.B., Sheridan A., Fishman N.O. Imipenem resistance among Pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol 2006, 27:893-900.
23. Furtado G.H., Bergamasco M.D., Menezes F.G., Marques D., Silva A., Perdiz L.B., et al. Imipenem-resistant Pseudomonas aeruginosa infection at a medical-surgical intensive care unit: risk factors and mortality. J Crit Care 2009, 24:e9-e14.
24. Zavascki A.P., Cruz R.P., Goldani L.Z. Risk factors for imipenem-resistant Pseudomonas aeruginosa: a comparative analysis of two case-control studies in hospitalized patients. J Hosp Infect 2005, 59:96-101.
25. Patel N., Harrington S., Dihmess A., Woo B., Masoud R., Martis P., et al. Clinical epidemiology of carbapenem-intermediate or -resistant Enterobacteriaceae. J Antimicrob Chemother 2011, 66:1600-1608.
26. Masterton R.G. The new treatment paradigm and the role of carbapenems. Int J Antimicrob Agents 2009, 33:105-110.